CD47 and glioblastoma: Researchers designed NAcp@CD47 nanocapsules to co-deliver anti-CD47 antibodies and STING agonists into GBM tissues, where the anti-CD47 component blocks the CD47-SIRPα axis to enhance phagocytosis by macrophages and microglia, thereby reducing immunosuppression.